REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
Firm withdraws sibutramine as FDA finds no patient group for which risk mitigation would result in sufficient benefit.
Firm withdraws sibutramine as FDA finds no patient group for which risk mitigation would result in sufficient benefit.